wclc 2026
gallery
Relive the energy of WCLC 2026 in Seoul through photos from across the Conference.
Access Password: WCLC2026
Watch
on-demand
Don’t wait to hear the research discussed in Seoul. Catch up on WCLC 2026 sessions and presentations, with on-demand access to key scientific content from the Conference.
CME Certificate/ Certificate of Attendance
Claim your CME Certificate/Certificate of Attendance from September 15 through December 31, 2026 on the IASLC Lung Cancer 360 platform.
How to Access Recordings and Slides
WCLC 2026 BY THE NUMBERS
E-Posters
The moments that
brought us together.
From the science on stage to the connections in between. Relive the energy of WCLC 2026 in Seoul.
Select a photo to explore
WCLC NEWS
-
Pumitamig Plus elfe-D Demonstrated Encouraging Early Efficacy in SCLC Across All Lines of Therapy and Dose Levels
Efficacy signals were observed regardless of patients’ smoking status or history of brain metastasis, as reported by Dr. Adam Schoenfeld during WCLC 2026.
-
Iza-Bren Delivers Promising Efficacy, Tolerable Safety Profile in Metastatic EGFR+ Non-Small Cell Lung Cancer
During his presentation at WCLC 2026, Dr. Alexander Spira said that Iza-Bren showed favorable outcomes across all dose levels for heavily pretreated patients with EGFR-mutated NSCLC.
-
Class III BRAF Alterations Associated With Shorter Survival in Stage IV NSCLC Following Immunotherapy
Dr. Alessandro Di Federico said results from a retrospective study suggest that patients with BRAF class II and III alterations have distinct clinicopathologic features and co-mutation patterns.
-
DeLLphi-309: Tarlatamab Extended-Interval Dosing Demonstrates Comparable Efficacy in Patients With SCLC
Dr. Jonathan Goldman said dosing regimens in which tarlatamab was administered every three or four weeks were efficacious and had safety profiles comparable to the currently approved schedule.
-
Findings Call Into Question the Value of Local Consolidative Therapy in Metastatic NSCLC After Dual Immune Checkpoint Blockade
The randomized LONESTAR trial showed no progression-free or overall survival benefit with local consolidative therapy after immune checkpoint blockade-based induction treatment in metastatic NSCLC without actionable genomic alterations.
-
Zidesamtinib Demonstrates a High Objective Response Rate in TKI-Naïve Patients with Advanced ROS1-Positive NSCLC
Researcher Alexander Drilon, MD, said at a median follow-up duration of 15.2 months, the objective response rate was 94%, and the complete response rate was 15%.
"
WCLC is always an impressive conference and I always find exciting information that I can use to develop new treatment regiments for my patients.
Yanyan Wang
IASLC Member – China
"
WCLC is always a highlight of my year! As a pathologist, it’s fabulous to attend a multidisciplinary conference with people sharing ideas and giving insights from every perspective.
Keith Kerr
IASLC Member – United Kingdom
"
The WCLC atmosphere is amazing! As a medical student, the opportunity to hear from and talk to the biggest doctors in the industry is an experience of a lifetime.
Sanad Alhushki
Medical Student – Jordan